Enrollment Success, Factors, and Prediction Models in Cancer Trials (2008-2019)-Reference-Cited by-全球学者库

Enrollment Success, Factors, and Prediction Models in Cancer Trials (2008-2019)

Published:2023-11 Issue:11 Volume:19 Page:1058-1068
ISSN:2688-1527
Container-title:JCO Oncology Practice
language:en
Short-container-title:JCO Oncology Practice

Author:

Zhang Siqi¹²³^ORCID,Zhang Jianrong⁴⁵^ORCID,Liu Sida⁶,Pang Herbert²^ORCID,Stinchcombe Thomas E.¹⁷^ORCID,Wang Xiaofei¹²⁸

Affiliation:

1. Duke Cancer Institute, Duke University, Durham, NC

2. Department of Biostatistics & Bioinformatics, Duke University School of Medicine, Durham, NC

3. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

4. Centre for Cancer Research & Department of General Practice and Primary Care, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia

5. Victorian Comprehensive Cancer Centre, Melbourne, Victoria, Australia

6. Department of Statistics, Florida State University, Tallahassee, FL

7. Duke University Medical Center, Durham, NC

8. Alliance Statistics and Data Management Center, Duke University, Durham, NC

Abstract

Study on 4,004 cancer trials found 49.1% of enrolment success rate with a decreasing tendency in 2008-2019.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Oncology (nursing),Health Policy,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/OP.23.00147

Reference43 articles.

1. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019

2. Relevance of randomised controlled trials in oncology

3. Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups

4. Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials

5. Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement